Given the addiction of many tumor cells to the neomorphic gain-of-function activities of mutp53 [123], HSP90 is considered a promising target for anti-cancer therapy, and HSP90 inhibitors that trigger mutp53 degradation are currently tested in clinical trials [17,124,125]. This evidence concerns the gene HSP90AA1 and neoplasm.